Umbilical Cord

Use of cryopreserved human umbilical cord tissue, known as Wharton’s jelly, may be an alternative treatment for tissue regeneration in patients with hip cartilage defects and osteoarthritis, according to published results.

Amniotic umbilical cord tissue may be an effective adjunctive therapy in patients undergoing meniscectomy, according to published results.

At 1-year follow-up, various cell-based injections were not superior to a corticosteroid injection for pain and radiological outcomes in patients with knee osteoarthritis, according to results published in Nature Medicine.

Umbilical cord milking — when blood is pushed through an unclamped umbilical cord toward the infant — appeared to be safe in preterm infants born between 28 and 32 weeks’ gestation, according to a study published in Pediatrics.

WASHINGTON — At the American Academy of Orthopaedic Surgeons Next Generation of Biologics Symposium, Scott Rodeo, MD, FAAOS, spoke about a clinical study that used gene-modified human umbilical vein endothelial cells in rotator cuff repair.

Elevated umbilical cord blood insulin concentration measured early after birth could be tied to high BP during childhood and adolescence, especially in children born preterm, according to a study published in Hypertension.

Published results showed patients undergoing high tibial osteotomy combined with a human umbilical cord blood-derived mesenchymal stem cell cartilage regeneration procedure may experience improved clinical outcomes and joint space width.

Intra-articular injection of amniotic membrane/umbilical cord particulate may reduce pain and improve function in patients with moderate to severe knee osteoarthritis, according to published results.

The FDA warned Liveyon Labs Inc. and Liveyon LLC, as well as their top executives, for processing and distributing unapproved products derived from umbilical cord blood, according to an agency news release.

Single UM171-expanded cord blood transplantation appeared safe and feasible among a small cohort of patients with hematologic malignancies who lacked suitable HLA-matched donors, according to results of a phase 1/phase 2 study published in The Lancet Haematology.